A phage nucleus-associated RNA-binding protein is required for jumbo phage infection.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
22 Sep 2023
22 Sep 2023
Historique:
pubmed:
4
10
2023
medline:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Large-genome bacteriophages (jumbo phages) of the
Identifiants
pubmed: 37790334
doi: 10.1101/2023.09.22.559000
pmc: PMC10542519
pii:
doi:
Types de publication
Preprint
Langues
eng
Déclaration de conflit d'intérêts
J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Algen Biotechnologies, Felix Biosciences, The Column Group and Inari. J.A.D. is Chief Science Advisor to Sixth Street, a Director at Johnson & Johnson, Altos and Tempus, and has research projects sponsored by Apple Tree Partners and Roche. G.W.Y. is an SAB member of Jumpcode Genomics and a co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Locanabio and Eclipse BioInnovations. G.W.Y. is a distinguished visiting professor at the National University of Singapore. G.W.Y.’s interests have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The Regents of the University of California have filed a provisional patent application for CRISPR technologies on which B.A.A., B.F.C., E.J.A., J.L., J.A.P., are J.A.D. are inventors.